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In June 2008, 2 additional endografts were approved for the treatment of thoracic aortic aneurysms in the United States. Their addition to the armamentarium of the aortic specialist allows for the expansion of anatomic criteria in the treatment of pa-
tients. Furthermore, additional experience has been obtained in centers of excellence 
with respect to off-label use of these prostheses. While early complications have been 
well recognized and documented through rigorous clinical-trial methods,1-3 addition-
al late complications (beyond 1 year) are now being seen. It is important to acknowl-
edge these issues and to develop strategies for the prevention and management of these 
rare but significant aspects of thoracic endovascular aortic repair (TEVAR). Compli-
cations can generally be divided into 2 categories: implantation and postimplantation.
 The complications encountered during the initial procedure may be related to the 
device or the procedure. Procedure-related complications, which have been well doc-
umented in the pivotal clinical trial publications,1-3 include neurologic, vascular-access, 
and ischemic problems. Vascular-access problems occur in approximately 15% to 20% 
of patients, for 2 reasons. Delivery catheters for thoracic devices are rather large (22F–
25F), and women, who have smaller arteries, are more strongly represented among 
patients who have thoracic aneurysms than among patients who have infrarenal aor-
tic aneurysms (male-to-female: thoracic, 60:40; abdominal, 80:20). Therefore, pros-
thetic conduits or alternative access sites such as the iliac artery or the aorta are needed 
in as many as 20% of the procedures. Failure to recognize this during case planning 
can lead to severe complications, including lower-extremity ischemia, increased risk 
of paraplegia, and death. Neurologic complications comprise both stroke and spinal-
cord-related problems. Currently, the risk of stroke appears to be more prominent than 
spinal-cord-related ischemia and may be associated with the number of manipulations 
and the location of the disease. Although device coverage of critical, branched great 
vessels can lead to ischemic stroke, this sequela can be minimized, if not eliminated, 
by careful preoperative imaging and planning. When the device implantation location 
extends into treatment zone 0 or 1 (Fig. 1), the risk of stroke increases significantly.2 
This may be the result of embolism, because the distribution of the strokes appears in 
both hemispheres and in the anterior and posterior distributions.
 Several studies have analyzed the factors that contribute to spinal cord ischemia,4 
which occurs in 3% to 10% of patients in most large series. Identified risk factors in-
clude length of coverage of the aorta, prior abdominal aortic surgery, pelvic occlusive 
disease, perioperative hypotension, and renal failure. Whether left subclavian artery 
coverage increases the risk is still controversial despite Eurostar data suggesting that 
it does. A recent publication by Feezor and colleagues3 implicated, as factors affecting 
the risk, not only the extent of treatment but also the location of treatment relative 
to the distal thoracic aorta. Prevention and management are grounded in traditional 
techniques, which include the maintenance of spinal cord perfusion pressure and the 
use of spinal drainage catheters.
 Although retrograde dissections have been reported as sequelae of the therapy, they 
fortunately are rare.5 Occurrences of retrograde dissection have been noted in the en-
dovascular repair of all thoracic aortic lesions and with all devices. Whether this se-
quela is device related or procedure related is diff icult to determine, given its low 
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the treatment of acute aortic conditions, and in most 
cases it requires emergent surgical management.
 Failure of arch conformation (Fig. 2) remains a for-
midable problem with these devices even after the 2 re-
cent device approvals. It is associated more commonly 
with nonaneurysmal lesions and with younger patients, 
who typically have a smaller radius or arch curvature. 
Failure of conformation can lead to device collapse and 
to resultant acute aortic obstruction and other sequel-
ae. Device modifications affecting delivery and deploy-
ment are currently under clinical investigation; it is to 
be hoped that these will mitigate, if not eliminate, the 
problem.
 During postimplantation follow-up, device collapse 
is also a possible sequela, as are device migration, endo-
leak, and prosthesis infection.5 Device migration can be 
associated with progression of the disease or with pa-
tient selection. To ensure minimal long-term compli-
cations, the selection of appropriate device-attachment 
sites is crucial. Endoleaks are not uncommon, and at-
tachment-site problems should be dealt with prompt-
ly because they are associated with a high incidence of 
major complications.
 Overall, TEVAR has shown excellent results in the 
clinical trial data. Device use outside the Instructions 
for Use increases the risk of sequelae associated with 
the therapy. Certain device and disease complications 
are rare and typically relate to patient selection and ana-
tomic variations. Device improvements and next-gener-
ation devices are under development and are in the early 
stages of clinical trial, in an effort to mitigate these prob-
lems.
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Fig. 1  Zones of implantation. Yellow indicates greater risk of 
stroke.
Fig. 2  Device malapposition (arrow) to inferior aortic arch wall.
